AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02372370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage pretreatment + MAL-PDT
Description: Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study NCT02372370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT
Description: Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study NCT03395587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard therapy
Description: temozolomide, fractionated radiochemotherapy
Study NCT02372370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT
Description: Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
Study NCT02372370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL Control.
Description: Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
Study NCT02372370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Untreated Control
Description: Untreated control. No interventions.
Study NCT02680509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathicotomy R3
Description: sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
Study NCT00234273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme in Adapted Physical Activity (APA)
Study NCT00234273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education primarily focused on dietary
Study NCT00234273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education primarily focused on dietary
Study NCT00886184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia.
Description: Induction of pre hospital therapeutic hypothermia.
Study NCT00886184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No early hypothermia
Description: Induction of therapeutic hypothermia only once arrived at hospital.
Study NCT04210778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive orientation to daily occupational performance (CO-OP)
Description: The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
Study NCT04210778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (BrainHQ, posit science)
Description: The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
Study NCT04210778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training (BrainHQ, posit science)
Description: The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
Study NCT04204122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox
Description: -FDA approved medication
Study NCT04204122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -The placebo is artificial tear drops
Study NCT03470961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tlymphocyte Globulins
Description: Induction therapy regimen in simultaneous pancreas kidney transplantation
Study NCT01161017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
Study NCT01161017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
Study NCT03679702 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Viveve System
Description: Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
Study NCT05226481 — intervention group
Intervention type: OTHER
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
Study NCT04529057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
Study NCT01913756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamalost (Norwegian traditional cheese)
Study NCT01913756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gouda-type cheese
Study NCT02710240 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared (NIR)
Study NCT00920374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™/Influsplit SSW®
Description: single intramuscular dose on Day 0
Study NCT01414036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care control
Description: Educational brochure, list of hospital and community resources
Study NCT01414036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
Study NCT03939520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone and nintedanib
Description: The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
Study NCT03939520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirfenidone or nintedanib
Description: The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Study NCT03939520 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pirfenidone or nintedanib
Description: The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
Study NCT01031693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study NCT01031693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study NCT02953275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: standard of care
Study NCT02953275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vedolizumab
Description: standard of care
Study NCT02953275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: added to vedolizumab
Study NCT02953275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: added to vedolizumab
Study NCT01565538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg Given orally
Study NCT01565538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 Given IV
Study NCT00764179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk enriched in proteins (2.15 g/100ml)
Description: Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)
Study NCT00764179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: milk with normal protein concentration (1.45g/100ml)
Description: Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)
Study NCT01043731 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic transvaginal hybrid anterior resection
Description: Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
Study NCT03134456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
Study NCT03940261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
Study NCT03940261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Moderate Intensity Training
Description: Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
Study NCT02655692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: FDA approved anesthetic medication with rapid acting antidepressant effects.
Study NCT02655692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Saline
Description: This is a saline placebo/non-active solution.
Study NCT01394770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
Study NCT01394770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
Study NCT03959709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
Description: On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
Study NCT03959709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement
Description: On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
Study NCT02339727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infants formula
Description: The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
Study NCT00690456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00690456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT00690456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy
Study NCT00690456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin continued at stable dose as background therapy
Study NCT03961256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide SR
Description: Exenatide SR 2 mg subcutaneous (SQ) weekly
Study NCT01334541 — intervention group
Intervention type: BEHAVIORAL
Intervention: SAFE VET
Description: All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol
Study NCT02391909 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vivotif
Study NCT02153788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: Temazepam 15 mg orally at bedtime
Study NCT02153788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03132454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03132454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03132454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03132454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT03470961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulins
Description: Induction therapy regimen in simultaneous pancreas kidney transplantation
Study NCT00530374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron Supplement
Description: Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
Study NCT00530374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
Study NCT01730417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: no carrier added metaiodobenzylguanidine
Description: Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
Study NCT00049517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given IV or as an injection
Study NCT00049517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00162682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Drug Combination Switching Criteria
Description: Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
Study NCT00162682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antiretroviral Drug Combination Switching Criteria
Description: Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
Study NCT00176891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Study NCT03411044 — intervention group
Intervention type: DEVICE
Intervention: Fitmore Hip Stem
Study NCT03453541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
Study NCT01680406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Study NCT03453541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: 0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
Study NCT01680406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT01680406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Study NCT00176891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laronidase ERT
Description: Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
Study NCT01691586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring
Description: Remote monitoring of ICD and heart failure data
Study NCT01691586 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In-Clinic check-ups
Description: Calender-based In-Clinic ICD check-up
Study NCT01691586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Clinic check-ups
Description: Calender-based In-Clinic ICD check-up
Study NCT04815460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity-interval training (HIIT)
Description: Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.